ArticleFrontiers in pharmacology2022

A preliminary study on drug switching strategy for second-line therapy after combination treatment of tyrosine kinase inhibitors and immune checkpoint inhibitors for unresectable hepatocellular carcinoma.

Renguo Guan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.